Voyageur Pharmaceuticals (TSXV:VM) LT-Debt-to-Total-Asset : 0.02 (As of May. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Voyageur Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Voyageur Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in May. 2024 was 0.02.

Voyageur Pharmaceuticals's long-term debt to total assets ratio increased from May. 2023 (0.01) to May. 2024 (0.02). It may suggest that Voyageur Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Voyageur Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Voyageur Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyageur Pharmaceuticals LT-Debt-to-Total-Asset Chart

Voyageur Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.04

0.01

0.02

Voyageur Pharmaceuticals Quarterly Data
	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.02	0.02	0.02

Voyageur Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Voyageur Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Nov. 2023 is calculated as

LT Debt to Total Assets (A: Nov. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Nov. 2023 )	/	Total Assets (A: Nov. 2023 )
	=	0.04	/	2.164
	=

Voyageur Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in May. 2024 is calculated as

LT Debt to Total Assets (Q: May. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: May. 2024 )	/	Total Assets (Q: May. 2024 )
	=	0.04	/	2.326
	=

Voyageur Pharmaceuticals (TSXV:VM) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Voyageur Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyageur Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Voyageur Pharmaceuticals Ltd (TSXV:VM) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

VYYRF:USA

Address

333 Southwest 7th Avenue, Suite 800, Calgary, AB, CAN, T2P 2Z1

Website

https://www.voyageurpharmaceuticals.ca

Voyageur Pharmaceuticals Ltd is engaged in the development of pharmaceutical ingredients (API) minerals. The company focuses on developing barium and iodine radiocontrast products and bromine-based pharmaceutical products. It provides its products for medical applications and diagnostics.

Executives

Charles Littlejohn

10% Security Holder

Voyageur Pharmaceuticals Headlines

No Headlines